Skip to Content

Generic Vistogard Availability

Vistogard is a brand name of uridine, approved by the FDA in the following formulation(s):

VISTOGARD (uridine triacetate - granule;oral)

  • Manufacturer: WELLSTAT THERAP
    Approval date: December 11, 2015
    Strength(s): 10GM/PACKET [RLD]

Has a generic version of Vistogard been approved?

No. There is currently no therapeutically equivalent version of Vistogard available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vistogard. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
    Patent 5,968,914
    Issued: October 19, 1999
    Inventor(s): von Borstel; Reid & Bamat; Michael K.
    Assignee(s): Pro-Neuron, Inc.
    The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
    Patent expiration dates:
    • October 19, 2016
      ✓ 
      Patent use: EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
  • Acylated uridine and cytidine and uses thereof
    Patent 6,258,795
    Issued: July 10, 2001
    Inventor(s): von Borstel; Reid Warren & Bamat; Michael Kevin
    Assignee(s): Pro-Neuron, Inc.
    The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
    Patent expiration dates:
    • July 10, 2018
      ✓ 
      Drug product
  • Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
    Patent 7,776,838
    Issued: August 17, 2010
    Inventor(s): von Borstel; Reid W. & Bamat; Michael K.
    Assignee(s): Wellstat Therapeutics Corporation
    The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
    Patent expiration dates:
    • August 17, 2027
      ✓ 
      Patent use: EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 11, 2018 - NEW PRODUCT
    • September 4, 2020 - NEW CHEMICAL ENTITY
    • December 11, 2022 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide